Skip to main content

Table 4 Adjusted Cox regression for clinical outcomes according to liver fibrosis status

From: Association between liver fibrosis and thrombotic or bleeding events in acute coronary syndrome patients

Liver fibrosis staged by LFS

MACCE

All-cause death

Cardiac death

Myocardial infarction

Ischemic stroke

Major bleeding

TVR

Stent

thrombosis

APRI

Low (N = 5639)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

Intermediate (N = 656)

1.14 (0.76–1.7)

0.97 (0.5–1.9)

1.43 (0.63–3.27)

1.91 (1.07–3.43)

1.15 (0.61–2.16)

0.99 (0.61–1.62)

1.13 (0.80–1.59)

1.35 (0.63–2.87)

p value

0.524

0.931

0.394

0.029

0.676

0.977

0.495

0.438

High (n = 91)

3.73 (2.03–6.87)

4.03 (1.66–9.78)

8.87 (3.32–23.72)

5.05 (1.76–14.5)

3.32 (1.17–9.43)

1.4 (0.44–4.45)

1.08 (0.44–2.66)

8.87 (3.29–23.94)

p value

< 0.001

0.002

< 0.001

0.003

0.024

0.572

0.862

< 0.001

AST/ALT ratio

Low (N = 3352)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

Intermediate (N = 2666)

0.92 (0.7–1.22)

1.13 (0.71–1.82)

0.92 (0.48–1.75)

1.14 (0.71–1.82)

0.69 (0.45–1.05)

0.89 (0.65–1.21)

0.87 (0.68–1.1)

0.99 (0.58–1.72)

p value

0.57

0.605

0.788

0.581

0.085

0.458

0.243

0.985

High (N = 368)

1.57 (1.02–2.43)

1.56 (0.77–3.13)

1.54 (0.62–3.8)

2.64 (1.29–5.41)

0.7 (0.3–1.62)

0.67 (0.33–1.37)

1.39 (0.90–2.14)

2.46 (1.06–5.67)

p value

0.042

0.214

0.352

0.008

0.408

0.276

0.141

0.035

Forns score

Low (N = 763)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

Intermediate (N = 4582)

1.55 (0.98–2.47)

2.1 (0.84–5.27)

2.89 (0.69–12.16)

1.26 (0.6–2.64)

1.62 (0.78–3.36)

1.26 (0.76–2.09)

0.91 (0.66–1.26)

1.36 (0.54–3.45)

p value

0.063

0.112

0.147

0.542

0.196

0.377

0.573

0.518

High (N = 1041)

1.77 (1.05–3)

4.46 (1.71–11.62)

5.59 (1.26–24.75)

1.32 (0.56–3.13)

1.08 (0.44–2.62)

1.57 (0.88–2.8)

0.74 (0.49–1.13)

1.88 (0.68–5.22)

p value

0.032

0.002

0.023

0.53

0.871

0.128

0.166

0.226

NFS

Low (N = 3109)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

Intermediate (N = 2842)

1.31 (1–1.72)

1.2 (0.76–1.92)

1.05 (0.55–2.03)

1.24 (0.78–1.96)

1.35 (0.88–2.07)

1.06 (0.78–1.43)

1.01 (0.81–1.27)

1.12 (0.65–1.96)

p value

0.052

0.434

0.875

0.364

0.168

0.702

0.928

0.679

High (N = 435)

2.73 (1.86–4)

2.77 (1.51–5.07)

3.49 (1.61–7.57)

2.77 (1.44–5.31)

2.12 (1.12–4.04)

1.24 (0.7–2.17)

1.08 (0.70–1.67)

4.08 (2.05–8.15)

p value

< 0.001

0.001

0.002

0.002

0.022

0.462

0.719

< 0.001

  1. LFS, liver fibrosis scores; MACCE, major adverse cardiac and cerebrovascular events; TVR, target vessel reconstruction; APRI, aspartate aminotransferase to platelet ratio index; AST/ALT ratio, aspartate aminotransferase to alanine aminotransferase ratio; NFS, nonalcoholic fatty liver disease fibrosis score